|
Mitotane |
|
0825542 29 04 Class 5. Class 10. Pharmaceutical preparations and substances. Surgical and medical apparatus and instruments; inhalers; parts and fittings for all the aforesaid goods.
The mutants were not complemented by a plasmid containing either gene alone pJSS102 and 103 ; , or containing nodPl and nod& in the wrong orientation with respect to the lac promoter pJSS100 ; . We replaced Tn5 in DsAux7 and in M3#5 with Tn5-233 to obtain a different resistance marker, and by reciprocal transductions showed that the two are closely linked 10 108 separated, indicating linkage within 0.5 kb ; . We used JSS30, one of the Cys- auxotrophs in which Tn5-233 was replaced with Tn5, to establish cotransduction of the insertions with the auxotrophic phenotype. We have named locus sua for sulfur amino the acid, as we found that either cysteine or methionine rescues the mutant. We constructed a triple mutant, sua, nod , nod& to show that sua is a distinct locus, and to test whether the strain was viable. The saa: : Tn5 mutation of JSS30 was transduced into a nodQI: : Tn5-132, nodQ2: : Tn5233 strain, creating JSS3 1. This triple mutant is viable on LB though it grows more slowly than JSS2l or JSS30. It was, as expected, an auxotroph requiring either methionine or cysteine. Since nodPQappeared to be functionally redundant.
A 14-year-old girl had a normal early medical history except for frequent episodes of otitis media and a "ganglion" that was excised from her left wrist when she was 6 months old. At the age of 71 2 years, she noted a soft-tissue mass over the lateral aspect of her left ankle. During the next year, additional periarticular masses developed involving the proximal right second finger, the left popliteal fossa, the left inferior patella, and the right and left lateral malleoli. Biopsies of the ankle and finger lesions and the skin were performed. At the age of 91 2 years the patient had the first of several episodes of transient, painful swelling of the periarticular masses and generalized cutaneous swelling. These episodes accompanied or followed exertion or a febrile illness and were selflimited, resolving spontaneously within a period of 72 hours.
Over the last few years, we focused on creating a solid foundation for long-term growth as highlighted by the strong performance of our anti-infectives in HIV, HBV and antifungals. Our strategy for building on this foundation continues to be through opportunities to acquire or in-license and partner with innovative!
It is used as a form of chemotherapy for malignancies such as lung cancer, testicular cancer, lymphoma, non-lymphocytic leukemia, and glioblastoma multiform teniposide is a prescribed medication mainly used to treat childhood acute lymphocytic leukemi alemtuzumab , bevacizumab , cetuximab , gemtuzumab , panitumumab , rituximab , trastuzumab monoclonal antibodies mab ; are antibodies that are identical because they were produced by one type of immune cell, all clones of a single parent cel alemtuzumab marketed as campath or campath-1h ; is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia cll ; and t-cell lymphom bevacizumab avastinâ ® is an anti-angiogenesis drug used in treatment of cance cetuximab erbitux® is a chimeric monoclonal antibody given by intravenous injection for treatment of colorectal cance gemtuzumab ozogamicin marketed as mylotarg ; is a monoclonal antibody used to treat acute myelogenous leukemi it is proposed that this article be deleted, because of the following concern: no references or indication of notabilit rituximab, sold under the trade names rituxanâ ® and mabtheraâ ® , is a monoclonal antibody used in the treatment of b cell non-hodgkins lymphoma and some autoimmune disorder herceptin logo trastuzumab herceptinâ ® is an anti-cancer therapy that acts on the her2 neu erbb2 ; recepto aminolevulinic acid , methyl aminolevulinate , porfimer sodium , verteporfin a photosensitizer is a chemical compound, used in the photodynamic therapy of cancers, that can be excited by light of a specific wavelengt d-aminolevulinic acid dala or î ´ -ala or 5-aminolevulinic acid ; is the first compound in the porphyrin synthesis pathwa methyl aminolevulinate is a sensitizer used in photodynamic radiation therap porfimer is a sensitizer used in photodynamic radiation therap verteporfin, otherwise known as benzoporphyrin derivative visudyneâ ® , is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneratio alitretinoin , altretamine , amsacrine , anagrelide , arsenic trioxide , asparaginase , bexarotene , bortezomib , dasatinib , denileukin diftitox , erlotinib , estramustine , gefitinib , hydroxycarbamide , imatinib , pentostatin , masoprocol , mitotane , pegaspargase , tretinoin alitretinoin is an antineoplastic agen altretamine also hexalen ; is a drug that is used to treat ovarian cance amsacrine is an antineoplastic agen anagrelide agrylinâ ® xagridâ ® , shire ; is a drug used for the treatment of essential thrombocytosis et; essential thrombocythemia ; r-phrases , s-phrases , supplementary data page structure and properties n, î µ r, etc.
One hind limb was placed in a rigid frame as shown in Figure 2. A pin drilled through the distal end of the femur held the limb firmly in the frame. The sciatic nerve and tibialis anterior muscle were surgically isolated. The nerve was placed on bipolar stimulating electrodes. A silk string attached the tendon of the muscle to an isometric tension transducer Statham UC3 with UL4-5 cell accessory ; . The resting tension of the muscle was adjusted to 200 gm using a screw attach and modafinil.
Limitations of the Literature A major limitation is the paucity of information. Information available to determine a mg kg toxic dose of methylphenidate following oral exposures is limited to five chart review studies conducted at poison centers three published and two in abstract form only ; and one case report 4549, 75 ; . With the exception of the prospective case series by Bailey et al. 45 ; , all of the case series were retrospective chart reviews; conclusions could be incorrect due to missing information. The possibility of inaccurate histories provided to poison centers must always be considered. As with the majority of studies reviewing cases of reported toxic ingestions, doses ingested cannot be confirmed. Three of the five case series 46, 48, 49 ; included intentional exposures self-harm and abuse for these cases, confirming the accuracy of the reported dose ingested is even more problematic. An additional limitation is that the studies, with the exception of the abstract by Marquardt et al. 44 ; , did not separate patients who received gastrointestinal decontamination and, therefore, it is unknown whether decontamination had an effect 4547, 49 ; . None of the three level 4 case series was specifically intended to determine the mg kg toxic dose of methylphenidate 45, 46, 49 ; . While mean mg kg ingested doses were calculated the case series by Foley et al. [46] and the abstract by Kim et al. [47] did not differentiate between IR, SR, and ER formulations, and the case series by Bailey et al. [45] did not differentiate between IR, SR, ER, OROS, CD, and LA formulations ; , the primary purpose of these studies was to profile methylphenidate exposure demographics and outcomes. Therefore, symptoms were presented as numbers of patients having symptoms or the percentage of patients having a given symptom. Consequently, determining which specific symptoms were associated with any mg kg dosage range was not possible. In one of the three case series 49 ; and one of the two abstracts 48 ; , it was not possible to separate the mg kg toxic doses between those less than 6 years of age and those 6 years of age and older. This limits the ability to determine if there is a threshold dose at which toxicity is likely to occur. With the exception of a statement in an abstract that hyperactivity and dilated pupils were noted in the two patients who reportedly ingested 12 mg kg 47 ; , none of the published reports provided a description of the adverse effects associate with a given mg kg dose reported. All that was reported was the total number or the percentage of patients who developed a specific symptom. This is problematic when trying to use the data to make decisions on home management, because one is not able to determine from the data how many children or adults developed symptoms not appropriate for home observation at a given mg kg ingested dose. Another limitation of the literature is the lack of toxic dose information for the CD, OROS, and LA formulations of methylphenidate. With the exception of the abstract by Marquardt et al. 48 ; and the case series by Bailey et al. 45 ; , the studies were conducted during years in which the CD, OROS, and LA formulations were not on the market. In the level 4 report by Bailey et al. 45 ; , the mean mg kg doses reported did not differentiate between IR, SR, ER, OROS, CD, or LA formulations. This leaves the abstract by Marquardt et al. 48 ; as the only information available on the toxic dose of modified-release formulations. For the 152 CD, OROS, and LA ingestions described in this abstract, outcomes were only described for 57 cases in which double doses had been taken. Mean doses for all three products CD, OROS, and LA ; were combined into one mean mg kg dose despite the different release rates of these formulations. Information on the toxic dose of the SR and ER formulations of methylphenidate are confined to the abstract by Marquardt et al. 48 ; in which 38 ingestions of SR or products were reported; however, only 11 were treated with observation alone. Kim et al. 47 ; and Foley et al. 46 ; did not differentiate mean mg kg toxic doses between the immediate-release formulations and the SR or ER formulations. The report by White and Yadao 49 ; only included ingestions of immediate-release products. There are no data on the consequences of methylphenidate patch ingestion. It is unknown how chewing the patch would affect drug delivery. CONCLUSIONS Key Decision Points for Triage The expert consensus panel chose to emphasize the importance of information that would be needed in order to make a sound triage decision for a patient with a known methylphenidate poisoning. These variables include the patient's intent, dose and formulation of the product, the presence of symptoms, and time of ingestion. The expert consensus panel agreed that in each case, the judgment of the specialist in poison information, the poison center medical director, or other poison center-affiliated clinicians might override any specific recommendation from this guideline. Patient Intent The panel concluded that all patients with suicidal intent, intentional abuse of methylphenidate, or in whom a malicious intent was suspected e.g., child abuse or neglect ; should be expeditiously transported to an emergency department, regardless of the dose ingested. Patients without these characteristics e.g., adults with definite.
52 MITOCHONDRIAL-PERMEABLE IRON CHELATORS PREVENT CARDIAC HYPERTROPHY IN THE MOUSE MODEL OF FRIEDREICH'S ATAXIA Whitnall M * , Puccio H, Koenig M and Richardson DR. * * Department of Pathology, University of Sydney, Sydney, New South Wales, 2006 AUSTRALIA. Tel: + 61-2-9036-6548 FAX: + 61-2-9036-6549 Email: d.richardson med yd .au Introduction: There is no effective treatment for the severe cardiomyopathy and neurological deficits that occur in the most common autosomal recessive disease, Friedreich's ataxia FA ; . The identification of potentially toxic iron Fe ; deposits in the mitochondria of patients with FA suggests that Fe may play a role in its pathogenesis due to cytotoxic radical generation. We examined if an Fe chelator that permeates the mitochondrion can prevent the pathology observed in a mouse model of FA, namely the Frda MCK conditional frataxin knockout mouse Puccio, H et al. 2001 ; Nature Genetics 27: 181-6 ; . This model reproduces the cardiac pathology observed in FA, including myocardial hypertrophy and mitochondrial Fe-loading. Materials and Methods: Frda MCK conditional frataxin knockout mouse, histological analysis, inductively coupled plasma mass spectrometry. Results and Discussion: In these studies, the lipophilic and mitochondrion- permeable ligand, pyridoxal isonicotinoyl hydrazone PIH ; , was used in combination with the hydrophilic chelator, desferrioxamine DFO ; . Iron chelation slowed total body weight loss in Frda MCK frataxin knockout mice. Significantly, treatment with the chelators markedly inhibited the development of myocardial hypertrophy and deposition of myocardial Fe deposits. While chelation removed excess Fe from cardiac tissue, it did not negatively impact on hematological indices. Our study shows that Fe chelation therapy prevented the cardiac hypertrophy observed in Frda MCK mice. These results indicate that mitochondrial Fe deposition is important in the pathogenesis of FA. Conclusions: Collectively, the results suggest that alterations in myocardial Fe metabolism play a role in the pathogenesis of FA and that mitochondrial permeable Fe chelators may be a useful therapeutic strategy and modicon.
Mitotane should be started at 1-2 grams m2 per day in four daily divided doses and increased by 0.5g-1.0g every 3-5 days as tolerated to a maximum of 8 grams m2 per day, until fat stores are saturated and therapeutic levels are achieved. To saturate the adipose tissue depots as quickly as possible, it is recommended that for the first 30 days, powdered mitotane tablets be mixed with a liquid nutrition formula composed of vegetal fat, such as Pulmocare, an enteral formula recommended for children with cystic fibrosis, or a chocolate milk shake. Mitotane exhibits a clear dose response curve. Serum levels must be maintained above 14mg L for effectiveness and below 20mg L to minimise side-effects. Such measurements, previously available in only some specialist centres cited below but now provided by the drug manufacturer, are vital to keep levels in a narrow therapeutic window 10, 21. Laboratoire HR Pharma, 19 Rue Frederick Lemaitre, 75020 Paris, France Tel + 33 140 331 or Fax + 33 140331231; e-mail hra-uk hra-pharma Dr Peter Heilman, Endocrine Dept, University of Heidelberg, Luisenstrasse 5 - Gebaude 8, 6915 Heidelberg Germany tel : + 06221 568614 Unpleasant side-effects, [e.g. gastrointestinal, neurological, dermal, haematological] are common and very careful monitoring is essential once the fats are saturated see below ; Mitotane readily impairs mineralocorticoid, thyroid, and parathyroid function, and continues or reasserts previously recovered ; suppression of the contralateral adrenal gland. Patients should be monitored regularly with electrolytes and glucose, calcium and thyroid function for the possibility of adrenal crises, particularly during periods of infection. Patients usually require both glucocorticoid and mineralocorticoid fludrocortisone ; replacement and should be closely followed by an endocrinologist Functional recovery of the adrenal zona glomerulosa and fasciculata has been reported following Mitotane therapy. Adverse Reactions to Mitotane.
| B53. Since we last interviewed you on FU1DATE, have you taken any prescription drugs for pain? YES. 1 NO and molindone.
For advice about money and benefits see chapter 11, page 81 & 82 . For information about the Mental Health Act see chapter 4.
From the Departments of Pathology and Immunology and Neurology and Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri, 63110 and the Laboratory for Neuronal Differentiation and Regeneration, RIKEN Center for Developmental Biology, 2-2-3 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan and moxifloxacin.
|
Where b is the number of M1 alleles in all affected children from heterozygous parents and c is the number of M2 alleles in affected children from heterozygous parents. The z score procedure given by Spielman and Ewens 1998 ; is used to calculate p-values for the S-TDT. This test can be applied to families where there is at least one affected sibling and one unaffected sibling, and not all siblings have the same genotype. The z score, whose two-sided p-value is approximated using the normal distribution, is calculated as z Y - represents the total observed number of M1 alleles in the affected siblings. For t total siblings in the family, a affected and u unaffected, and r that are M1 M1 and s that are M1 M2 , summing over families gives A V 2r au[4r t - r - s.
This fascinating collection of essays brings gender issues to the foreground to redress a profound imbalance in the historiography of the Yishuv, the Jewish community in Palestine, and in the early years of the State of Israel. Although male discourse still dominates, recent studies have begun to create an authentic and multifaceted Hebrew-Israeli voice by examining the contributions of women. This research has led to a number of basic questions: What was the reality of life for women in Jewish society in Ottoman and Mandatory Palestine Eretz Israel ; , and in the early years of the State? What was the contribution of women to the renewal of Israeli society and culture? What is the place of gender perceptions in the study of the new local identity? The original articles in this anthology forge an innovative response to one or more of these questions, and reflecting the state of research in the field. Offered by the editors as "an appetizer" to whet appetites for further study, this volume will serve as an important catalyst and contribution to contemporary research that calls for a revised national discourse, one that expresses the world of women and issues of gender and mrv.
33. UKPDS study group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes UKPDS 36 ; , prospective observational study. BMJ 2000; 321: 412-19.
Partners in Health Update is a publication of the Provider Communications department for the exchange of information and ideas among the AmeriHealth provider community. Suggestions are welcome. CONTACT INFORMATION: Rose Sutkowski Managing Editor Charleen Baselice Production Coordinator Provider Communications AmeriHealth 1901 Market Street 35th Floor Philadelphia, PA 19103 providercommunications amerihealth and multivitamin.
16. D. Flot, K. Friese, O. Haufe, H. Modrow, M. Panthfer, A. Reich, M. Rieger, G. Wu, M. Jansen, Structure Analysis of Alkaline Earth Endohedral Fullerenes M C74 Co OEP ; 2 C6H6 M Sr, Ba ; , in Molecular Nanostructures: XVII Int'l Winterschool Euroconference on Electronic Properties of Novel Materials", edited by H. Kuzmany et al., AIP Conference Proceedings 685, New York, American Institute of Physics, 2003, p. 37. 17. T. Gavrilko, G. Puchkovskaya, I. Sekirin, B. Engelen, M. Panthfer, J. Baran, H. Ratajzcak, Possible manifestation of proton disorder in -KIO3HIO3 crystal in its IR spectra, J. Mol. Struct. 692 2004 ; 237. 18. M. Panthfer, U. Wedig, H. Brumm, M. Jansen, Geometric and Electronic Structure of Polymeric C70-Fullerides: The case of [C703-], Solid State Sciences, 6 2004 ; 619. 19. K. Friese, M. Panthfer, G. Wu, M. Jansen, Strategies for the structure determination of endohedral fullerenes applied to the example of Ba C74 Co octaethylporphyrin ; 2C6H6 Acta Cryst. B 60 2004 ; 520. 20. A. Reich, M. Panthfer, H. Modrow, U. Wedig, M. Jansen, The Structure of Ba C74, J. Am. Chem. Soc. 126 2004 ; 14428. 21. M. Panthfer, D. Shopova, M. Jansen, Crystal Structure and Stablility of the Fullerene Chalcogene Co-Crystal C60Se8CS2 Z. Anorg. Allg. Chem., im Druck. 22. M. Schulz-Dobrick, M. Panthfer, M. Jansen, Supramolecular Arrangement of C60 and Phenol into a Square Packing of - interacting and Hydrogen-bonded Rods in C60 5 C6H5OH Europ. J. Inorg. Chem., eingereicht.
The Partnership for Prescription Assistance offers a single point of access to more than 475 public and private patient assistance programs, including more than 180 programs offered by pharmaceutical companies. These programs can provide access to more than 2, 500 prescription medicines, including a wide range of generics. Through a tollfree number 1-888-4PPA-NOW ; or user-friendly Web site pparx ; , patients can find out if they may be eligible for one or more patient assistance programs. Patients that call the toll-free number speak to a trained specialist who asks a series of questions and mails contact information and applications for the programs for which the patient potentially qualifies. Patients that access the program via the Web site can immediately download the forms for completion and even use the Application Wizard to simplify the process. While the Partnership for Prescription Assistance has matched more than two million individuals with a patient assistance program that appears to meet their needs, millions more could benefit if they simply knew that help was available. In an effort to help spread the word about the Partnership for Prescription Assistance, the "Help is and murine.
Proved. and he now voluntarily anihulates with a walker. He has mild muscle atrophy.
Cheap mitotane online
1. Transmitter LCD No Display: a. Make sure fresh alkaline batteries are installed into the Transmitter b. Check that the batteries are properly installed into the battery compartment and the polarity is correct. c. After taking out the batteries from the Transmitter, wait for at least 1 minute before putting fresh batteries into the Transmitter. 2. a. b. Batteries in the DC Receiver Get Hot: Take out the batteries from the Receiver battery compartment immediately. Switch the Receiver to `OFF' position. Wait for at least 1 minute before putting batteries back into the Receiver battery compartment. d. Switch the Receiver to `REMOTE' position. 3. Receiver Cannot Turn on the Fireplace: a. Make sure fresh alkaline batteries are installed into the Receiver DC Receiver only ; . b. Make sure the output cables are securely connected to the Receiver and the gas valve. c. For DC Receiver, switch the Receiver to `ON'. For AC Receiver, press the ON OFF button on the Receiver. Use a multimeter to measure the resistance between the output cables. The multimeter should read zero ro very low resistance. 4. a. b. Receiver Does Not Respond to the Transmitter: Make sure the Receiver is at `REMOTE' position. DC Receiver only ; Make sure the Receiver is connected to the power source. Make sure the Receiver has learned the transmitter coding. Refer to 6 and muse.
Order mitotane
Merbromin 2 ; , and mercuric oxide yellow 1 as a bulk chemical ingredient, and only 2 products merbromin mercurochrome ; solution ; had active drug uses. The agency does not believe either of these products that had active drug uses is currently marketed because of a final rule that the agency issued on April 22, 1998 63 FR 19799 ; . In that final rule, the agency declared merbromin and other mercury active.
Infestations and ectoparasites continued ; reference resources, 175 risk factors, 174 lice, 177-188 body lice, 182 clinical features of, 177, 182-183 diagnosis of, 177, 182-183 epidemiology and etiology of, 177, 182-183 head lice, 177-182, 178f, 180t-181t pubic lice, 183-184, 183f reference resources for, 184-187 treatment and management of, 177-179, 180t-181t, 182-184 scabies, 189-194 clinical features of, 189-192, 190f-191f diagnosis of, 189-191, 190f-191f epidemiology and etiology of, 189 reference resources for, 194 treatment and management of, 191-193, 192t-193t Inflammatory bowel disease. See IBD inflammatory bowel disease ; . Insect bites, 71-72, 75, 109t Interferon-alpha, 127-129, 128t-129t Intertrigo, 79, 159-160 Intravenous. See IV intravenous ; . Introductory concepts. See Fundamental concepts. Inverse psoriasis, 79 Iodine tincture, 117-118 ISDA Infectious Disease Society of America ; guidelines, 32-33 Isoleucyl-transfer RNA inhibitors, 20t Itraconazole, 135-137, 136t, 153-157, IV intravenous ; , 30t, 62-63 antibiotic therapies, 63-68 catheters, 77 drug use, 30t, 62-63 Jock itch. See Tinea cruris. Keratoacanthoma, 117t Keratolysis, pitted. See Pitted keratolysis. Ketoconazole, 138-141, 142t-143t, 162t-163t, Ketolides, 16t Klebsiella spp, 14t Knock-down resistance, 179-180 KOH potassium hydroxide ; , 134-135, 140f, 146f Kytococcus sedentarius, 85 Lactic acid, 117-118 Lamisil and Lamisil AT, 142t-143t, 162t-163t. See also Terbinafine and mycostatin and mitotane.
Undertake rehabilitation of facilities jointly with ia provide the ia with supplies for maintenance activities provide ia with water delivery and planting schedules one month prior to start of cultivation and notify of any unavoidable delays or changes deliver in a timely manner, adequate water to the headgate of the lateral of the ia develop and implement training programs to develop ia capacity to undertake its activities regularly inspect and monitor ia activities regarding implementation of contract assist ia in conflict resolution beyond its capacity to resolve.
MCL represents 2% to 8% of nonHodgkin's lymphomas. It predominantly affects older males 60 + years ; Most patients 75% to 100% ; present with widespread lymph node involvement; enlargement of the spleen occurs in 35% to 75%; and bone marrow involvement is found in 60% to 90% of patients. Although the mucous tissue lining the gastrointestinal tract may appear normal, abnormal cells are found in up to 80% of patients with MCL. Fifteen to 30% of patients will develop polyps of lymph tissue in the gastrointestinal tract. Up to 9% of patients will develop involvement in their brain or spinal fluid and mysoline.
That appeared to extend caudal to the hippocampal formation Fig. 1, left ; . This illustration is at variance with Scoville's written description which likely represents his best estimate ; depicting the resection as sparing at least one third of the caudal hippocampus. The MRI analysis provided evidence of a smaller lesion Fig. 1, right ; , which is not entirely consistent either with Scoville's figure or with his written description. The right side of Figure 1 provides a modification of the original Scoville illustration that is more consistent with the MRI findings.
Microbiological cultures not on indicative list or in a form that meets the criteria for Category A e.g. some HG2 pathogens or Class 2 GMMs ; Category B ; Infectious waste contaminated with radioactive material Category A.
Dr. James M. Scheiman, AGAF, said the evidence shows that PPIs plus NSAIDs provide similar risk reduction for adverse GI events as coxibs.
Incubated at 37oC, for 30 minutes. After being washed twice in PBS for 10 minutes, specimens were embedded in Fluoroprep bioMrieux Italia SpA ; , and applied upside-down on a microscope slide. The light from the bound fluorescein conjugated antibodies was detected by an experienced microbiologist, blinded to clinical data, through a Leitz Laborlux S fluorescent microscope, with a 20 objective. A positive reaction was indicated by the defined and complete fluorescence of larvae on the slide. Results were expressed as the greatest serum dilution that gave a positive result.
|
Each February the Orchid Societies Council of Victoria Judging Panel bestows a number of Victorian Orchid of the Year Awards on premier orchids flowered during the previous twelve months. The usual awards are: Victorian Orchid of the Year Victorian Award of Distinction of the Year Victorian Award of Quality of the Year Victorian Australian Native Orchid of the Year species or hybrid ; Victorian Cultural Certificate of the Year Victorian Cymbidium of the Year Victorian Laeliinae of the Year species or hybrid ; Victorian Cymbidium of the Year species or hybrid ; Victorian Masdevallia of the Year species or hybrid ; Victorian Odontoglossum of the Year Odontoglossum Alliance, species or hybrid ; Victorian Paphiopedilum Species of the Year Victorian Paphiopedilum Hybrid of the Year Victorian Other Hybrid of the Year excludes hybrids listed above ; Victorian Other Species of the Year excludes species listed above ; Victorian Seedling of the Year flowering for the first time ; Extra awards may be created at the discretion of the Judges, who also have the right to withhold an award if they consider that there are no entries of a sufficiently high standard. The owner of the Victorian Orchid of the Year will receive the S. & E. Bato Perpetual Trophy an original painting of Rossioglossum grande by Syd Monkhouse ; . This trophy must be returned by August 1 of the following year, when it will be replaced with a signed print of the above painting, which may be retained permanently. The other winners will receive either a silver or bronze OSCOV medallion, as determined by the Judging Panel. Conditions of entry are: Entry is open to any grower. It is free to all members of OSCOV Member Societies but there is a fee for all others. Interstate entries are eligible provided that the orchid has been presented for judging at a meeting or show judged in Victoria by the OSCOV Judging Panel. The orchid must have been owned and grown by the exhibitor for at least six months two years in the case of Victorian Cultural Certificate of the Year ; . All orchids that have received OSCOV awards during the current year will be entered automatically, but any other orchid that has flowered and been photographed during the current year may also be submitted for consideration. Orchids which have won any Victorian Orchid of the Year award previously are ineligible in the same category, unless they receive a higher award in a subsequent flowering. One set of digital photographs is required. This will remain the property of OSCOV, which has the right to use it for publication, training and or promotion without cost. Each set of digital photographs must include the front view of a single flower and a view of the whole plant. Other views are optional. In each case the subject should fill the viewing area as fully as practicable. Entries must be made on the official entry form, a copy of which is available from the Secretary of any OSCOV Member Society or from the Secretary of the OSCOV Judging Panel currently Mr. Bill Mather, 70 Winston Road, Viewbank, VIC 3084 ; . These entries, together with relevant digital images, must be received by the Awards Secretary of the OSCOV Judging Panel currently Mr. Stephen Early, LPO Box 8071, Carrum Downs VIC 3201; telephone 03 9786 1938 ; by January 31 of the following year. All entries will be judged by the OSCOV Judging Panel in February. Judging for Victorian Orchids of the Year shall be determined by a preferential voting system and modafinil.
INFORMATION ii ; in respect of shares held in electronic form, to those "deemed members" whose names appear in the statements of beneficial ownership furnished by National Securities Depository Limited NSDL ; and Central Depository Services India ; Limited CDSL ; as at the end of business on Friday, May 30, 2003. Unclaimed Dividends Pursuant to Section 205A of the Companies Act, 1956, unclaimed dividends up to and including for the financial year 1993-94 have been transferred to the General Revenue Account of the Central Government. The Shareholders who have not encashed their dividend warrants relating to financial year s ; upto 1993-94 are requested to claim the amounts from the Registrar of Companies, Maharashtra, nd CGO Complex, 2 Floor "A" Wing, CBD Belapur, Navi Mumbai 400 614 Telephone: 022 ; 2757 6802 in the prescribed form which will be furnished by the Registrar and Transfer Agent, Karvy Consultants Limited on request. The amount of dividend for the year 1994-95 which remained unclaimed for 7 years from the date of declaration has been transferred to the Investor Education and Protection Fund established by the Central Government pursuant to Section 205C of the Companies Act, 1956. The dividend for the following years remaining unclaimed for 7 years from the date of declaration are required to be transferred by the Company to the said account and the various dates for transfer of such amounts are as under: Financial Year 1995-96 1996-97 1997-98 Dividend No. 108 109 110.
This is especially relevant for the monitoring of cortisol substitution that therefore requires measurements of free cortisol and ACTH levels. In this respect, a literature report Hague, May et al. 1989 ; indicates the occurrence of adrenal crisis in two patients treated with mitotane requiring the use of high amount of steroid substitution. These adrenal crises were associated with evidence of liver enzyme induction shortening of antipyrine half-life during mitotane treatment ; , which may have played an important role in the occurrence of the steroid resistance. A substantial percentage of the patients treated show signs of adrenal insufficiency. It therefore appears necessary to institute steroid replacement in those patients. Since Lysodren increases plasma level of steroid binding proteins, free cortisol and ACTH determinations are necessary for optimal dosing of steroid substitution. Liver function tests NOS abnormal: The hepatotoxicity of mitotane has been reviewed Neuman, Bruckert et al. 2001 ; in a retrospective review of 10 patients with Cushing syndrome no patient had an adrenal carcinoma in this series ; , after a mean dose of 9 g per day. In all patients a raise of plasma cholesterol was noted. Before treatment, 3 patients had an increase in plasma alanine aminotransferase ALAT ; . During treatment all patients had an increase of either alanine aminotransferase ALAT ; or gamma-glutamyltransferase gamma-GT ; , or both. The maximum increase was 6 times the upper normal value, for mean doses of approximately 9 grams per day. The increase was detected after 2 weeks on treatment in 4 patients, and within 4 months in the others. Treatment discontinuation led to normalisation within 4 months to one year. No case of liver failure were reported. Blood and the lymphatic system disorders: Cases of leucopenia, decrease in leucocytes, platelets or erythrocytes were reported in some patients without any conclusion as to whether or not these effects are related to mitotane, or to the underlying disease of the patients. A reversible pancytopenia has been reported in a patient treated by mitotane 3g day ; for a paraneoplastic Cushing's syndrome Andres, Vinzio et al. 2001 ; . Hypercholesterolaemia HDL ; has been reported during mitotane treatment Vassilopoulou-Sellin and Samaan 1991; Maher, Trainer et al. 1992; Gebhardt, Moolenaar et al. 1993 ; . The proposed mechanism of action is a blockade of cytochrome P450-mediated reactions leading to a down-regulation of hepatic cholesterol synthesis. The use of cholesterol-synthesis inhibitors statins ; reverses this effect and can be proposed in association with mitotane treatment. Safety in special populations No specific data addressing the safety of mitotane in children were included in the Marketing Authorisation Application. However, based on the safety profile of the product observed in adults and based on the information included in the US product information for Lysodren, the summary of product characteristics for Lysodren states that neuro-psychological retardation may be observed during mitotane treatment. In such cases, thyroid function should be investigated in order to identify a possible thyroid impairment linked to mitotane treatment. ypothyroidism and growth retardation may be also observed during mitotane treatment. Safety related to drug-drug interactions and other interactions Spironolactone: Mitotane should not be given in combination with spironolactone since this product may block the action of mitotane. This association is contra-indicated. Warfarin and coumarin-like anticoagulants: Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-like anticoagulants. Substances metabolised through cytochrome P450: Mitotane has been shown to have an inductive effect on cytochrome P450 enzymes. Therefore the plasma concentrations of the products metabolised via cytochrome P450 may be modified. In the absence of information on the specific P450 isoenzymes.
| REFERENCES AOBA, T. and YAGI, T. 1982 ; : Effects of Acid-Dissolution on Thin Ground Sections of Enamel Caries Studied by Microradiography and X-ray Microbeam Diffraction, J Oral Pathol 11: 191-200. ARMSTRONG, W.D. and BREKHUS, P.J. 1937 ; : Chemical Constitution of Enamel and Dentin, J Biol Chem 120: 677-687. BACKER DIRKS, 0. 1966 ; : Post-eruptive Changes in Dental Enamel, J Dent Res 45: 503-511. CHEN, P.S.; TORIBARA, T.Y.; and WARNER, H. 1956 ; : Microdetermination of Phosphorus, Anal Chem 28: 1756-1758.
There was no apparent detriment to any functional component of the muscle group and the improvement lasted for about 6 months. Not surprisingly, the authors noted that there was a low patient satisfaction with this procedure as there was apparently little change rendered by the treatment. Injections of radish calves will most likely be limited to very select patients who are greatly distressed by the contour and size of their calves.
A total of 357 EDP courses were administered median 6, range 113 ; . Associated side effects are reported in Table 4. The most frequent toxicity was hematologic: grade 2 toxicity for white blood cells were recorded in 10% of patients at recycle and in 33% of patients at nadir. There was a toxic death due to septic shock caused by prolonged neutropenia. The most common extra-hematologic side effects were gastrointestinal, neurologic, asthenia and myalgias, but were less than grade 3 in most cases. Neurologic toxicity was central in two patients, peripheral in 14 cases, and was both central and peripheral in five cases. All patients received at least one treatment cycle and 38 52.8% ; patients completed the treatment plan six cycles ; , including three patients who received 8, and 13 cycles respectively. The EDP regimen was delayed 1 week for 30 patients 41.7% ; , and 2 weeks for 14 patients 19.4% ; . Leukopenia and infections were the principal reasons for these delays. Dose reduction of all the three EDP drugs was performed in seven patients due to hematologic toxicity. The planned dose of mitotane 4 g daily ; was regularly received by 21 patients.
|
319 destruction of zona glomerulosa can occur at this dosage as well as the iatrogenic Addison's disease can be triggered Schechter et al. 1973; Feldman et al. 1992 ; . The patient is monitored by ACTH stimulation test or UCCR during therapy in order to prevent the unexpected induction of hypoadrenocorticism Feldman 1996; Rijnberk 1996 ; . The other treatment protocol is the method of non-selective adrenocorticolysis to initiate Addison's disease. This treatment protocol was worked out by Rijnberk and Belshaw 1988 ; . Mitotane is continued at a maintenance dose of 50-75 mg kg b. w. daily in toy breeds up to 100 mg kg b.w. daily ; for 25 consecutive days. Since the objective of this protocol is to induce hypoadrenocorticism, the patient is given glucocorticoids and mineralocorticoids from the third day of therapy. The substitution therapy is life-long; its interruption can cause exitus. Monitoring of this treatment protocol is less laborious than during the selective adrenocorticolysis. The UCCR is measured only before the onset of therapy and one month after cessation of treatment. Continuous monitoring in stabilised patient is recommended in both treatment protocols every four months of therapy. Rijnberk and Belshaw 1992 ; reported up to 33% recurrence rate within one year when using the method of non-selective adrenocorticolysis mentioned above, ACTH stimulation test or UCCR can be used for evaluation of changes in cortisol production during mitotane therapy. Other indirect indices of cortisol production rate of PU PD, polyphagia, evaluation of changes in haematological and biochemical profile ; are inaccurate and therefore associated with high risk when establishing the length of initial phase of therapy Feldman 1996 ; . Only pre-treatment clinical and laboratory signs are therefore mentioned in the present work. The immunoreactive cortisol measurement in urine was used as well as UCCR for direct quantification of changes in cortisol production during therapy. Therapy with mitotane can be summarised as follows: The duration of the initial therapy ranged from 10 to 64 days. The mean length of initial therapy dose of mitotane 25 mg kg b.w. ; was 17 13 days, the median of the length of initial phase of therapy was 14.5 day. By Kintzer and Peterson 1991 ; the mean length of initial therapy during mitotane treatment at a dosage of 50 mg kg b. w. daily was nine days, with the possible fluctuation from 5 to 60 days. Ferguson et al. 1992 ; reported the mean length of initial therapy during the same dosage of mitotane 14 days with the possible fluctuation from 2 to 35 days. The cumulative induction dose of mitotane ranged between 250 and 1600 mg kg b. w. Kintzer and Peterson 1994 ; reported the mean induction dose of mitotane in patients with the pituitary-dependent hyperadrenocorticism 400-500 mg kg b. w., while in patients with adrenocortical tumour the induction dosages are approximately ten times higher. Further goal of this work was to find if linear dependence exists between the length of initial therapy and the level of the initial UCCR. We have found no linear dependence between both parameters. The obtained results documented the strongly individual reaction of patients during mitotane therapy which is to a great extent unpredictable. There is a need of an individual approach in each patient, because there is no generally applicable scheme of the length of initial therapy that could be employed on the basis of the knowledge of initial cortisol production. Using the selective adrenocorticolysis, frequent and expensive monitoring is necessary for the desired effect of therapy as well as for reduction of the risk of iatrogenic hypoadrenocorticism. Hodnocen odpovdavosti ps s centrlnm hyperadrenokorticizmem na lbu mitotanem, sledovn vodn fze terapie ve vztahu k iniciln hodnot pomru kortizol kreatinin v moi Hlavnm clem prce bylo hodnocen odpovdavosti ps s centrlnm hyperadrenokorticizmem na lbu mitotanem. Byl sledovn vztah mezi dlkou vodn fze terapie a hodnotou inicilnho pomru kortizol kreatinin C C ; v moi. K lb bylo pfiistoupeno celkem u 14 ps centrlnm hyperadrenokorticizmem. Byl zvolen terapeutick protokol.
Another recent addition to the EMEA website is a "quick-look" leaflet on orphan medicinal product designation in the European Union. This useful leaflet provides a clear overview of the rationale for and benefits of orphan product designation, and emphasises that orphan status designation is not an endorsement for the use of the product concerned in the condition specified. The quality, safety and efficacy of the medicinal product cannot be evaluated until the application for marketing authorisation has been submitted. p.
PMN 106 assay ; were incubated at 0 C with varying concentrations of 125Ilabeled HLE and CG, and bound and free ligand were quantified as described under "Experimental Procedures." The binding data were corrected for non-specific binding of ligands and then analyzed by the Scatchard method to determine the number of binding sites per cell and the binding affinity KD ; of the PMN plasma membrane sites for HLE and CG on PMN. b Data are the mean S.E.; n 4 separate experiments performed in quadruplicate.
FIGURE 15.--Figures 15A and 15B are images from the popliteal lymph node of a female B6C3F1 that drained a hind leg with a neoplastic mass. There is effacement of the cortical, paracortical and medullary regions by a neoplastic mass as well as invasion of the capsule and perinodal adipose tissue Figure 15A ; . Higher magnification shows an eosinophilic "strap cell" indicative of rhabdomyosarcoma Figure 15B, arrow ; , a tumor of striated muscle origin. Microscopic focusing of the tissue can allow striations to be seen within the strap cell cytoplasm. Figures 15C and 15D are images from a male F344 rat lymph node, also with a metastatic rhabdomyosarcoma. In addition to strap cells, immunohistochemical and ultrastructural features can also aid in the diagnosis of rhabdomyoscaromas. The most useful ultrastructural feature is the presence of myofilaments actin and myosin filaments ; . They are typically arranged in parallel bundles, or myofibrils, with recognizable electron dense Z bands. These are the equivalent of the cross striations seen with light microscopy. Immunohistochemistry is the preferred diagnostic method to confirm the diagnosis of rhabdomyosarcoma. The most useful antibodies are those against vimentin, desmin, actin, myoglobin, myosin and titin. Since various antigens are expressed differently, it is important to use a panel of antibodies for immunohistochemical characterization of these tumors.
|
|
|
